Lv2
170 积分 2024-03-17 加入
[Efficacy and safety of Anlotinib in the treatment of advanced sarcoma]
2天前
已完结
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: a single-arm, phase 2 trial
2天前
已完结
Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study
2天前
已完结
Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study
2天前
已完结
Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
2天前
已完结
Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
2天前
已完结
Pan‐cancer efficacy and safety of anlotinib plus PD‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial
2天前
已完结
Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy
2天前
已完结
Stereotactic body radiotherapy in pancreatic adenocarcinoma
7天前
已完结
Cellular and molecular mechanisms of Hedgehog signalling
1个月前
已完结
皖公网安备34019202002308
